Genelux Corporation (GNLX)

NASDAQ: GNLX · IEX Real-Time Price · USD
5.56
-0.30 (-5.12%)
At close: Feb 3, 2023, 4:00 PM
5.57
+0.01 (0.18%)
After-hours: Feb 3, 2023, 7:29 PM EST
-5.12%
Market Cap 131.30M
Revenue (ttm) n/a
Net Income (ttm) -15.58M
Shares Out 23.62M
EPS (ttm) -0.66
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 14,760
Open 5.71
Previous Close 5.86
Day's Range 5.52 - 5.85
52-Week Range 5.35 - 7.94
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About GNLX

Genelux is a clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Our most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus (VACV), a stable DNA virus with a large engineering capacity. We expect to be in the process of obtaining Institutional Review Board approvals and negotiating clinical trial agreements to begin enrollment for our Phase 3 regi... [Read more]

Industry Health Care
IPO Date Jan 26, 2023
Employees 14
Stock Exchange NASDAQ
Ticker Symbol GNLX
Full Company Profile

Financial Performance

Financial Statements

News

Genelux IPO prices at bottom of range

Genelux Corp. priced its initial public offering at $6 a share, the low end of its $6 to $7 a share range, for its stock market debut Thursday on the Nasdaq under the symbol GNLX. With 2.5 million sha...

1 week ago - Market Watch

Genelux Corporation Announces Pricing of Initial Public Offering

WESTLAKE VILLAGE, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (“Genelux” or “the Company”), a clinical-stage immunotherapy company focused on developing a pipeline of next-generation...

1 week ago - GlobeNewsWire

Genelux sets IPO terms, as the biotech could be valued at up to $165 millino

Genelux Corp. GNLX, has set terms for its initial public offering, in which the California-based biotechnology company focused on treating difficult-to-treat tumors could be valued at up to $164.99 mi...

4 months ago - Market Watch